A three-dose course of the AstraZeneca vaccine is effective against the Omicron variant of the coronavirus. It was the pharmaceutical company itself that communicated it today, citing data from a laboratory study at the University of Oxford. The study, not yet published in medical journals subject to review by other scientists, showed that levels of antibodies against the Omicron variant after the booster dose were higher than those recorded in people who had contracted Covid-19 and they were cured of it.
Furthermore, after a three-dose course of the vaccine, neutralization levels against the Omicron variant were similar to those recorded against the Delta variant after two doses, AstraZeneca said. The Anglo-Swedish house said the researchers who conducted the study in Oxford were independent of those who had worked together with the company on the Vaxzevria vaccine. Scientists and governments are working to bolster defenses against Omicron with injections and therapies, as the variant threatens to become globally dominant and has pushed to renew pre-holiday restrictions to contain infections.
Novavax’s Covid vaccine also demonstrated “a strong immune response” against the Omicron variant and other strains of the coronavirus, according to a series of initial data. However, the pharmaceutical company stated that the neutralization against Omicron was “four times lower” than that of the original strain of the virus. This indicates that a booster dose or a new ad hoc vaccine against the new variant may be useful. The third dose of the vaccine administered six months after the first two indicated, in fact, an increase in antibodies to the levels of protection observed in past clinical studies, where the vaccine was approximately 90% effective. Novavax could start producing a specific vaccine for Omicron in early January,
However, new data from Scotland and South Africa suggest that people affected by the Omicron variant have a significantly lower risk of hospitalization than those who contracted previous strains of the virus, thus promising that immunity acquired with vaccination or a previous one. infection remains effective in warding off serious illness even in the case of Omicron. The University of Edinburgh study, drawing on the medical records of 5.4 million people in Scotland, where the new variant became dominant last week, found that the risk of hospitalization for Covid-19 is two lower thirds with the Omicron variant compared to the Delta strain. Another study published online by researchers from
To dampen the enthusiasm and the White House: it has warned that Pfizer’s pill to fight Covid-19 will not be fully available for six months. The complex nature of the drug means that in order to have the 10 million doses that are in order on the market one has to wait until June. Pfizer’s Covid-19 antiviral pill, Paxlovid, received emergency clearance from the U.S. Food and Drug Administration Wednesday for use on people 12 years of age and older with mild or moderate Covid-19 who are at risk of develop more severe symptoms. Despite the green light from the FDA, the president’s health advisors, Joe Biden, quickly warned that it would take months for the company to produce and distribute all 10 million treatments already ordered. (All rights reserved)

Previous articleFrom Cannes to Le Iene, feet on display between oddities and fetishism
Next articleDIY hand cream: how to make and ingredients